Novo Nordisk remains a Strong Buy with new FDA approvals and AI-driven efficiencies boosting growth.

Novo Nordisk is rated a Strong Buy as it shifts to a high-volume, lower-price model, improving operational efficiency and leveraging AI for cost savings. Recent FDA approvals for Wegovy HD and Awiqli, along with a strategic partnership with OpenAI, support ongoing innovation and supply chain independence. Despite challenges like patent expirations and price pressures, the company's valuation remains attractive with a P/E of 12.29 and a free cash flow yield near 4.7%. Upcoming catalysts include growth in US Wegovy volumes, oral Wegovy rollout, potential share buybacks, and new obesity therapy developments.